Previous 10 | Next 10 |
REDWOOD CITY, Calif., Dec. 13, 2019 (GLOBE NEWSWIRE) -- In the largest-ever liquid biopsy study for treatment selection in advanced breast cancer, investigators demonstrated in an 800-patient prospective clinical trial that the Guardant360 ® assay accurately detected biomarkers that c...
In the foreseeable future, will the growth of the company require sufficient equity financing so that the larger number of shares outstanding will largely cancel the existing stockholders' benefit from this anticipated growth? - Phillip Fisher Every industry has its norm. In bioscience i...
REDWOOD CITY, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Despite longstanding medical guidelines recommending biomarker testing for all patients with metastatic colon cancer, a new study published in JCO Precision Oncology shows that only 40 percent of patients are tested according to guid...
Guardant Health (NASDAQ: GH) commenced trading on Oct. 4, 2018. If you had the foresight and luck to get IPO shares at its $19 debut price, your investment would be up 391%. A $10,000 investment would be worth just over $39,000, based on today's share price, which is hovering around $74. Mo...
Shares of Guardant Health (NASDAQ: GH) increased nearly 12% last month, according to data provided by S&P Global Market Intelligence . The liquid biopsy pioneer reported solid third-quarter 2019 operating results highlighted by revenue growth that continues to impress. In fact, the busi...
Introduction Over the past year, there has been a lot of coverage on Seeking Alpha about Exact Sciences ( EXAS ) and Guardant Health ( GH ), two companies playing in the emerging precision oncology space . This article focuses on comparing the two companies which are both chasing the same m...
Chances are, you know someone whose life has been affected by cancer, a disease that will kill more than 600,000 people in the United States this year. Guardant Health (NASDAQ: GH) is fighting back. The medical diagnostics company markets liquid biopsies (blood tests) that he...
Many things we spend on our money on are wants rather than needs. We could live without cars, smartphones, and streaming services if we had to. But what about healthcare? It's a need. What's more, demand for healthcare-related products and services is growing. An increasing senior population in...
In this week's episode of Industry Focus: Healthcare , host Shannon Jones talks with Motley Fool medtech guru Brian Feroldi about three earnings reports from three fantastic medtech companies: Guardant (NASDAQ: GH) , the leader in liquid biopsies, and the game-changing diabetes player...
Investment Thesis Guardant Health, Inc. ( GH ), a company providing cancer screening tests, has seen its top-line rising exponentially in recent quarters amid growing margins. The share price has surged ~17% higher since the recent upward guidance to 2019 outlook. The growing volumes and p...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (C...
2024-05-11 09:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highligh...